<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140005366A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140005366</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13864096</doc-number><date>20130416</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>30</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>07</class><subclass>K</subclass><main-group>16</main-group><subgroup>30</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc></classifications-cpc><classification-national><country>US</country><main-classification>5303873</main-classification><further-classification>5303881</further-classification><further-classification>435449</further-classification><further-classification>53038815</further-classification></classification-national><invention-title id="d0e43">GENERATION OF A CANCER-SPECIFIC IMMUNE RESPONSE TOWARD MUC1 AND CANCER SPECIFIC MUC1 ANTIBODIES</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>12444360</doc-number><date>20091022</date></document-id><parent-grant-document><document-id><country>US</country><doc-number>8440798</doc-number></document-id></parent-grant-document><parent-pct-document><document-id><country>WO</country><doc-number>PCT/DK2007/050139</doc-number><date>20071004</date></document-id></parent-pct-document></parent-doc><child-doc><document-id><country>US</country><doc-number>13864096</doc-number></document-id></child-doc></relation></continuation><us-provisional-application><document-id><country>US</country><doc-number>60848997</doc-number><date>20061004</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Cancer Research Technology Limited</orgname><address><city>London</city><country>GB</country></address></addressbook><residence><country>GB</country></residence></us-applicant><us-applicant sequence="01" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Kobenhavns Universitet</orgname><address><city>Copenhagen N</city><country>DK</country></address></addressbook><residence><country>DK</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>Clausen</last-name><first-name>Henrik</first-name><address><city>Holte</city><country>DK</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>Burchell</last-name><first-name>Joy</first-name><address><city>London</city><country>GB</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>Mandel</last-name><first-name>Ulla</first-name><address><city>Holte</city><country>DK</country></address></addressbook></inventor><inventor sequence="03" designation="us-only"><addressbook><last-name>S&#xf8;rensen</last-name><first-name>Anne Louise</first-name><address><city>Copenhagen S</city><country>DK</country></address></addressbook></inventor><inventor sequence="04" designation="us-only"><addressbook><last-name>Tarp</last-name><first-name>Mads Agervig</first-name><address><city>Kgs. Lyngby</city><country>DK</country></address></addressbook></inventor><inventor sequence="05" designation="us-only"><addressbook><last-name>Taylor-Papadimitriou</last-name><first-name>Joyce</first-name><address><city>London</city><country>GB</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>Cancer Research Technology Limited</orgname><role>03</role><address><city>London</city><country>GB</country></address></addressbook></assignee><assignee><addressbook><orgname>K&#xf8;benhavns Universitet</orgname><role>03</role><address><city>Copenhagen N</city><country>DK</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">The present invention provides a method for inducing a cancer specific immune response against MUC1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide. Another aspect is an antibody generated using the immunogenic glycopeptide and the use of said antibody in therapy and diagnosis.</p></abstract></us-patent-application>